3h quinidine

Radiolabeled quinoline antimalarial drugs were obtained from the following vendors: [³H]-chloroquine (18.8 Ci/mmol), GE Healthcare; [³H]-quinine (20 Ci/mmol) and [³H]-quinidine (20 Ci/mmol), American Radiolabeled Chemicals, Inc.

Non-radiolabeled chemicals were obtained from Merck/Sigma-Aldrich. Calcein AM was purchased from Invitrogen. All chemicals were of analytical grade. ³H-digoxin ([³H(G)], 23.8 Ci/mmol), ³H-prazosin ([7-methoxy-³H], 77.4 Ci/mmol) and Ultima Gold XR scintillation fluid were purchased from PerkinElmer (Waltham, MA, USA). ³H-quinidine ([9-³H], 20 Ci/mmol) and ³H-talinolol ([ring-³H(G)], 20 Ci/mmol) were purchased from American Radiolabeled Chemicals (St. Louis, MO, USA). ³H-fexofenadine ([³H], 4.9 Ci/mmol) was purchased from Moravek Biochemicals Inc. (Brea, CA, USA). The Tetro™ cDNA Synthesis Kit was purchased from Meridian Bioscience (London, UK). The Light Cycler^® 480 SYBR Green 1 master kit was obtained from Roche Applied Science (Foster City, CA, USA). 4–15% precast polyacrylamide gel (Invitrogen, Carlsbad, CA, USA) and ProSieve^TM QuadColor^TM Protein Marker (4.6–300 kDa) were obtained from Lonza (Basel, Switzerland). Monoclonal human ABCB4 (P3II-26, sc-58221) primary antibody was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), and ABCB1 (C219) primary antibody was purchased from Enzo Life Sciences, Inc (Lausen, Switzerland). Secondary anti-mouse IgG antibody was obtained from ThermoFisher (# 62-6520). The BCA protein assay kit was obtained from Thermo Scientific (Rockford, IL, USA).

[³H]-CQ (specific activity, 37 Ci mmol⁻¹), [³H]-quinine (specific activity, 20 Ci mmol⁻¹), [³H]-quinidine (specific activity, 20 Ci mmol⁻¹), [³H]-vinblastine (specific activity, 7.8 Cimmol⁻¹), [³H]-vincristine (specific activity, 5 Cimmol⁻¹), [³H]-amantadine (specific activity, 33 Cimmol⁻¹) and [³H]-piperaquine (specific activity, 15 Cimmol⁻¹) were obtained from American Radiolabeled Chemicals, GE Healthcare or Quotient Biorsearch. Other chemicals were provided by Sigma-Aldrich.